Larry Magid: Testing prescription, over-the-counter continuous glucose monitors
A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...
Expanding EPD Business Supports ABT Stock Amid Macro Issues
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...
The Gazette12d
Abbott banks on glucose monitors, new launches to ride out China, currency hit
has seen a large boost to sales from strong demand for FreeStyle Libre - its continuous glucose monitor. Abbott had been facing supply issues for its Libre devices and said it will meet the demand ...
The Motley Fool: A diverse health care dynamo
Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, ...
Abbott forecasts in line annual profit on medical device sales
Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...
Motley Fool: A health care dynamo
Abbott Laboratories (NYSE: ABT) is a well-diversified health care company, with four distinct units: medical devices, ...
Why Is Abbott Stock Trading Higher On Thursday?
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices.
Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.